We have located links that may give you full text access.
CLL-240 Frequency of IKZF3 L162R Mutation in B-Cell Lymphoproliferative Disorders.
Clinical Lymphoma, Myeloma & Leukemia 2022 October
A mutation of AIOLOS/IKZF3, a member of the IKAROS family transcription factors has been identified as a putative driver of chronic lymphocytic leukemia (CLL) through large-scale WES studies of CLL patients, with a frequency of ~3% CLLs. The mutation has been detected uniquely as a hotspot mutation (L162R), localized within the DNA binding domain, conferring a gain-of-function by altering DNA binding specificity and expression of IKZF3 target genes, resulting in overexpression of B-cell receptor (BCR) signaling genes. Apart from CLL, IKZF3 mutations are rarely described in other B-cell lymphomas. In this study, we aimed to evaluate the frequency of IKZF3 mutations in lymphoproliferative B-cell disorders. By reviewing the literature and reanalyzing the cBioPortal database, IKZF3 was reported to be mutated in 31 cases, including 16 CLL, 10 DLBCL, 1 MCL, 1 MW, and 3 FL. Interestingly, the p.L162R hotspot mutation identified in CLL occurred in 17/31 cases, suggesting a selection of this gain-of-function mutation and a common mechanism of lymphomagenesis. Targeted NGS sequencing of a 13-gene panel, including exon 5 of IKZF3, was used to analyze a French multicentric prospective cohort of 650 CLL patients. We confirmed the presence of the IKZF3-L162R mutation with a frequency of 2% (n=13/650) in CLL. We next designed a droplet digital PCR assay, allowing the detection of the IKZF3-L162R mutation with high sensitivity in a retrospective cohort of 48 patients harboring an MYD88 L265P mutation, including 2 DLBCL and 46 Waldenstrom's macroglobulinemia (WM) cases. Among the 48 patients tested, the mutation was detected in 3 patients with WM disease (3/46; 6.5%) with a variant allelic frequency (VAF) of 0.7%, 1%, and 3%. These patients were symptomatic with anti-MAG antibodies or organomegaly. Targeted NGS sequencing confirmed the presence of the IKZF3-L162R mutation in the samples with VAF >1%. Altogether, IKZF3-L162R mutation occurs in CLL but also in other B-cell neoplasms with similar frequencies, suggesting a common mechanism of lymphomagenesis related to the dysregulation of BCR-signaling genes. We are currently sequencing more samples, including marginal zone lymphoma, to better appreciate the distribution of this mutation among B-cell lymphomas.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app